Suppr超能文献

自闭症谱系障碍的精神药理学管理

Psychopharmacology Management in Autism Spectrum Disorder.

作者信息

Salpekar Jay A, Scahill Lawrence

机构信息

Neuropsychiatry Center, Kennedy Krieger Institute, Johns Hopkins University School of Medicine, 1741 Ashland Avenue, Baltimore, MD 21205, USA.

Emory University School of Medicine, Marcus Autism Center, 1920 Briarcliff Road, Atlanta, GA 30329, USA.

出版信息

Pediatr Clin North Am. 2024 Apr;71(2):283-299. doi: 10.1016/j.pcl.2023.12.001. Epub 2024 Jan 5.

Abstract

Persons with autism spectrum disorder (ASD) may have other psychiatric conditions that warrant treatment. Symptoms may not be easy to discern from rigidity or irritability that are sometimes considered to be constituent parts of ASD. Pathophysiology that involves hyperexcitable neurons and anomalous connectivity may provide justification for using psychopharmacologic agents, although nonmedical strategies may also be effective. Hyperactivity, irritability, and tantrums with or without aggression may be rational targets for psychopharmacological intervention. The best-studied drug class to date has been the second-generation antipsychotics targeting irritability.

摘要

患有自闭症谱系障碍(ASD)的人可能有其他需要治疗的精神疾病。这些症状可能不容易与有时被认为是ASD组成部分的刻板或易怒区分开来。涉及神经元过度兴奋和异常连接的病理生理学可能为使用精神药物提供依据,尽管非药物策略也可能有效。多动、易怒以及伴有或不伴有攻击行为的发脾气可能是精神药物干预的合理目标。迄今为止,研究最多的药物类别是针对易怒症状的第二代抗精神病药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验